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Abstract: The popularity of multiparticulate formulations (MPs) as a paediatric dosage form 
continues to increase. MPs comprise of multiple small units that are easy-to-swallow. Currently, 
MPs are commonly manufactured into unit doses that are either swallowed whole or opened prior 
to administration. While this is an acceptable approach, dosing is envisioned to be optimised with 
a “standard” paediatric device which can better harness the flexible dosing potential of MPs. We 
evaluated a novel oral syringe (SympfinyTM, HS Design, Morristown, NJ, USA) that is being 
developed as a tool to dispense and administer MPs to children. Forty children, 4–12 years old, 
received 0.5, 1.2, and 2.0 mL doses of placebo MPs using the oral syringe with spring water or a 
drink of choice to complete sample intake. Acceptability was recorded as those able to completely 
swallow the dose and participants also rated dose acceptability on a 5-point scale. The ability to 
completely swallow the dose decreased as dose volume increased; the smallest dose was completely 
swallowed by 87.5% (35/40) children, and 69.4% (27/39) of children confirmed their willingness to 
take the sample as a daily medicine. Larger doses, 1.2 and 2.0 mL, gave values of 55% and 57.5% for 
the doses completely swallowed and 58.8% and 51.72% for willingness to take the sample as a daily 
medicine, respectively. Use of a drink of choice showed no increase in swallowability as compared 
with water. The novel oral syringe being developed is an appropriate device for dispensing doses 
flexibly and administering neutral tasting MPs directly to the mouth in the lower dose range 
without the need for a co-administration vehicle in children aged 4–12 years. 
Keywords: multiparticulates; administration device; acceptability; paediatric formulation; 
mouthfeel; oral syringe 
 
1. Introduction 
A paediatric population has distinct requirements for oral drug delivery compared to adults due 
to their continuing development. Children present different anatomical, physiological and 
psychological characteristics which influence the approach to the administration of medicines [1]. 
Conventional formulations are not always appropriate for this patient group leading to dose 
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manipulation and compounding of existing products [2]. Thus, an oral drug formulation specifically 
developed to provide dose flexibility to suit the dosing requirements across all age groups is desired. 
Multiparticulate (MP) dosage forms, such as sprinkles, pellets and granules, comprise multiple 
units (typically below 2.5 mm [3]). These were introduced in the 1940 s and now more than 65 
products are available in the US for paediatric populations [4]. MPs can be coated to provide the 
desired release profile or to achieve taste masking [5], which is known to improve patient compliance. 
Due to their small size MPs provide many advantages over single-unit systems. Their small size 
dramatically improves their ease of swallowing over single unit tablets, plus multi-unit composition 
allows flexible dosing [6]. Since each unit contains a small amount of drug, the recommended dose 
can be prepared by means of a counting device (such as in the case of minitablets) or measuring a 
given weight/volume. For these reasons, MPs offer a viable alternative to conventional liquid 
formulations for children [1]. 
The acceptability of a dosage form, defined as “an overall ability of the patient and caregiver to 
use a medicinal product as intended” [7], is determined by the attributes of the product and the user. 
For MPs, the acceptability characteristics of the formulation include taste [7], particle size, volume 
and mouthfeel [8,9]. The ease of administration is also vital from the user’s point of view; this includes 
consideration of the number of units, dosing device and (where relevant) the co-administered vehicle. 
The choice of administration device is an integral part of the overall quality and acceptability of the 
medication [10]. Existing MP medicines are typically provided as prefilled unit dose capsules or 
sachets where the appropriate dose is pre-packaged. The capsule/sachet may be opened to allow the 
MPs to be dosed to the patient directly onto the tongue [11], or given on a spoon [12]. MPs are often 
mixed with soft food, with applesauce being the most widespread vehicle used, to aid administration 
[4]. However, this requires additional testing to confirm chemical compatibility with the product and 
the suitability of vehicle in the target population [13] as well as the global availability of the vehicle 
being used. Administration of MPs with soft food is not always viable, for example, due to absence 
of an appropriate vehicle in which the drug product is stable or no availability of an appropriate 
vehicle in some parts of the world. This highlights that there is a need for an alternative, simpler 
administration mode. 
It was demonstrated that MPs are acceptable to children when dosed on a spoon with water as 
the co-administered vehicle [14], yet a medicine spoon does not allow flexibility in dosing that may 
be required for a paediatric MP product. A prototype of a novel oral syringe (Sympfiny™, HS Design, 
Morristown, USA) has been designed to dispense and administer MPs directly into a patient’s mouth. 
This option provides enhanced flexibility in dosing from multidose containers, and may reduce costs, 
as compared with single-dose preparations [15]. 
Regulatory agencies in Europe and the United States [1,16] recommend confirming acceptability 
of a product in the target population, yet, without a clear guideline on the methodology to be used. 
In current practice, various methods and measures are used to assess acceptability of medicines [17]. 
When children are used as subjects, the assessment tool should be simple and easy for the 
children/caregivers to understand. For instance, simple Likert-type scales and hedonic scales have 
been often employed to evaluate specific sample attributes and/or overall acceptability of medicines 
in paediatric populations [18,19] as they are appropriate to use from the age of four years [20]. In 
addition, the proportion of participants able to swallow a dose has been recently used as a simple 
measure of patient acceptability in various placebo studies [14,21–23]. A combination of tools can 
minimise the bias of using a single method to report acceptability [17]. 
This study aimed to evaluate the acceptability of placebo multiparticulates (MPs) administered 
using the oral syringe Sympfiny™ in healthy child volunteers. The effect of the quantity as 
determined by the volume of MPs dosed on acceptability was investigated. Secondary objectives 
included understanding if the drink provided at the time of administration improved acceptability. 
Data collected as participant reported outcomes (PRO) was complemented by researcher reported 
outcomes (RRO). 
  
Pharmaceutics 2020, 12, 806 3 of 14 
 
2. Materials and Methods 
2.1. Materials 
Mannitol 350 mg/g placebo microsphere cores were used as model placebo MPs. The MPs 
contained stearyl alcohol (carrier wax), poloxamer 407 (pore former) and mannitol. They were 
manufactured using the melt spray congeal spinning disc atomisation technology (Lo., J.B., 2009). 
MPs were coated with the reverse enteric barrier membrane Kollicoat Smartseal 30 D at a coating of 
10% weight gain, after coating MPs the batch was blended with 2% talc to help mitigate any tackiness 
or agglomeration upon storage. MPs were produced and coated under good manufacturing practices 
by Pfizer (Groton, CT, USA). The final MPs were passed through a screen set-up to retain cores 150–
425 µm in size and displayed a monodisperse size distribution centered at approximate 246 µm (D50) 
in size. 
A prototype 2-mL oral syringe (Figure 1) was used to dose, dispense and administer MPs. 
Sympfiny™ is an oral syringe and bottle adapter combination which uses a valve system to control 
the flow of MPs. When the oral syringe is connected to the bottle adapter, both valves open to allow 
MPs to flow into the syringe. Upon removal, both valves close stopping the flow of MPs. Please refer 
to the Supplementary Materials (instructions for use) and the website for additional detail https://hs-
design.com/sympfiny/. 
 
Figure 1. (A) Sympfiny™ oral syringe and bottle adapter combination; (B) scheme of oral syringe use; 
top: connecting a syringe to the bottle adapter, bottom: dispensing a dose (reproduced with 
permission of HS Design). 
2.2. Study Design 
A cross-over, open-label, partially randomised, single-centre study design was used to evaluate 
the acceptability of MPs administered using an oral syringe. The study was approved by the 
University of Birmingham Research Ethics Committee (ERN_18-1870, 24th June 2019). 
The study involved children from 4 to 12 years old; exclusion criteria were as follows: children 
with swallowing difficulties, children with allergies to peanuts, gluten and/or lactose. Participants 
were recruited via associated groups and networks from the research team via advertisements placed 
on relevant noticeboards and within University newsletters. Additionally, some participants were 
recruited at the study site where visitors expressed an interest in the study. 
2.3. Procedure 
The study took place in a designated room at Thinktank Science Museum (Birmingham, UK). In 
advance of the study, each participant or their legal guardian was provided with a copy of the 
(A) (B) 
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participant information sheet. Before the study began, adult participants gave written informed 
consent for the study for the child in their care, and child participants gave verbal assent. 
Parents/carers were asked to prepare and administer four doses of MPs, one by one, to the child 
in their care; self-administration (by the child) was permitted. Participants were provided with the 
oral syringe, one bottle containing MPs, drinking spring water, a cup that could be used to 
expectorate the sample, crackers, and a PRO questionnaire (Figure 2). Adult participants were given 
written instructions on how to use the oral syringe (Supplementary Materials), with no additional 
verbal training during the study. The doses were administered in the following order: 0.5 mL, 1.2 mL 
and 2.0 mL, correlated to a mass of MPs of 0.32, 0.78 and 1.29 g, respectively, with water followed by 
2.0 or 1.2 mL with a drink of choice (for the fourth dose, the volume was reduced during the study 
from 2 mL to 1.2 mL to ease the burden on the paediatric participants; this change occurred from 
participant #16 onwards). Participants had free access to drinking water (bottled spring water) as 
required to complete sample intake. For the last dose, a drink of choice—milk, squash (fruit cordial 
diluted with water) or fruit juice were provided as an alternative to water. Before each dose, children 
were recommended to use a palate cleanser—room temperature drinking water (bottled spring 
water), followed by a piece of lightly salted cracker (Jacob’s, or Schar gluten-free) [24]. Prior to each 
dose, the child was asked if they were willing to continue with the study; the adults or the children 
in their care were able to withdraw from the study at any point. 
 
Figure 2. Table set up for one child for the assessment of the acceptability of MPs administered using 
an oral syringe (Sympfiny™). 
2.4. Data Collection 
2.4.1. Participant Reported Outcomes 
Participant reported outcomes were collected using a paper-based structured questionnaire that 
was completed by the children immediately after each administered dose. Participants could also 
provide a voluntary written description of the sample, which was used to facilitate interpretation of 
results. 
Children evaluated the samples for four palatability attributes (grittiness, volume, mouthfeel 
and taste) using 5-point hedonic facial scales (Table 1), replicating the previous methodology from a 
similar study of Lopez, Mistry, Batchelor, Bennett, Coupe, Ernest, Orlu and Tuleu [14]. After 
completion of hedonic ratings, participants answered the following question: “If this was a medicine 
and you were sick, would you be willing to take this every day?”. In addition, the number of children 
who reported that they felt “bits” of MPs in their mouth following administration was established 
(self-reported, the mouth was not inspected after swallowing). The total volume of water consumed 
for each sample was calculated as the difference in the mass of the cup of water before and after 
sample intake (ρH2O ≈ 1 g/mL). 
 
Oral syringe  
 
Bottle of MPs 
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2.4.2. Researcher Reported Outcomes 
Each participant was observed by a researcher during the administration of MPs. The following 
outcomes for each dose were reported: “completely swallowed”, “partially swallowed”, “chewed 
on”, “sample spat out”, “sample got stuck in throat”, “refused to take sample”, similar to previous 
studies [14,22,23]. During and after administration of the dose, the researcher recorded specific 
negative facial expressions displayed by the child (multiple responses from the following were 
recorded: “lips pressed (together)”, “nose wrinkling”, “eyes squeeze”, “brows pulled together and 
lowered”, “head shake”, “voice disgust”). The sum of negative facial expressions was calculated as 
an indicator of participants’ hedonic response indicating their discomfort. In addition, spontaneous 
verbal judgement of the samples was recorded on researcher observation sheets. 
Table 1. Tools used by children to assess their experience of swallowing the multiparticulate 
formulation. 
Questions Assessment Tool 
Please rate the grittiness of the sample. (Grittiness means that you can feel 
‘bits’ in the sample) 
5-point hedonic scale with a 
dual scale 
(not gritty–very gritty) 
(no bits–lots of bits) 
What did you think of the overall volume of the sample? (Volume means the 
amount you had to take) 
5-point hedonic scale 
(unmarked) 
What did you think of the overall mouthfeel of the sample? (Mouthfeel 
means how the sample felt in your mouth) 
5-point hedonic scale 
(unmarked) 
What did you think of the overall taste of the sample? 
5-point hedonic scale 
(unmarked) 
Can you still feel any of the “bits” in your mouth? yes/no 
If this was a medicine and you were sick, would you be willing to take this 
every day? 
yes/no 
Any other comments about this sample free text 
2.5. Data Analysis 
Data from researcher observations and child participant-reported outcomes were treated as 
categorical data. Childrens’ ratings on a 5-point hedonic scale were assigned scores from 1 to 5 (where 
a score of 1 referred to a positive quality; and 5 to negative quality). Differences between scores given 
for two different doses (pairwise) were assessed using Wilcoxon’s signed rank test with Bonferroni 
correction. For comparison of multiple doses, a Friedman test was used. 
Hedonic scores were used as an indicator of acceptability. Criteria to demonstrate acceptability 
was defined as a hedonic score ≤3 (neutral or positive face) [25]. Acceptable/unacceptable hedonic 
scores were then tested for association with other acceptability measures using Wilcoxon rank test. 
The association between demographic data and outcome measures was examined using the 
Pearson Chi2 test (χ2). To study age-related differences, three age groups were compared: 4–6, 7–9, 
and 10–12 years old. The volume of water consumed was treated as a non-normally distributed 
continuous variable (based on Shapiro–Wilk test). 
For all tests the level of significance p < 0.05 was used unless stated otherwise. Statistical analysis 
was performed using SPSS statistical software version 26 (IBM Corp, Armonk, NY, USA). 
3. Results 
The study included 40 paediatric participants. There were ten cases of discontinuation based on 
a child’s withdrawal, which occurred at different times of the study. The data collected up to the 
point of participant withdrawal were included in the analysis. Thirty children completed the full 
course of the study. Participants’ demographics are given in Table 2. Within the study population, 
87.5% (35/40) of children had experience of taking oral medicines from an oral syringe. 
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Table 2. Participants demographics. 
 Children (n = 40) 
Number of Participants Frequency Percent (%) 
Gender   
Male 21 52.5 
Female 19 47.7 
Age (years)   
4 6 15 
5 10 25 
6 4 10 
7 4 10 
8 9 22.5 
9 1 2.5 
10 4 10 
11 1 2.5 
12 1 2.5 
Ethnicity * 
Asian 6 15 
British 8 20 
Mixed 1 2.5 
White 23 57.5 
Missing ** 2 5 
Does the child in your care have experience of taking oral medicines from an oral syringe (e.g., Calpol)?  
Yes 35 87.5 
No 2 5.0 
Missing ** 3 7.5 
Has the child in your care previously experienced problems with swallowing medicines? 
Yes 6 15 
No 31 77.5 
Missing ** 3 7.5 
If you answered YES to the previous question, what caused problems with swallowing medicines? 
Size 0 0 
Taste 6 100 
Texture 1 16.7 
Aftertaste 1 16.7 
Dry mouth 0 0 
Other, please give details 0 0 
* Free text was permitted for participants to complete ethnicity; ** participant did not answer the question. 
3.1. Success of Swallowing the MPs Dose 
The majority of children managed to swallow the dose of MPs (as opposed to those who partially 
swallowed the sample, spat out or refused it). The success of swallowing depended on the dose 
volume (Chi2, p < 0.05); the first dose administered, 0.5 mL (0.32 g), was completely swallowed by 
87.5% (35/40) children (Table 3). As a larger dose volume was presented to the child, the proportion 
of children who only partially swallowed the sample increased, suggesting difficulty in swallowing 
large volumes of MPs in a single administration/mouthful. Likewise, the number of children who 
refused to take a dose increased with dose volume. While only one child refused the 0.5-mL dose, the 
larger doses were refused by 11 children (27.5%). The age of the children that refused the sample 
ranged from 4 to 8 years old. The children who spat out the dose tended to refuse the next dose (5 
out of 7 occasions). 
For the fourth dose given, children chose the drink taken with the sample from a selection of 
milk, fruit juice or fruit squash. It was assumed that a drink, other than water, could improve the 
acceptance and hedonic response to the MPs. However, no improvement in the success of swallowing 
the dose, nor palatability was found for the doses given with a drink of choice (dose–volume 
matched, Wilcoxon Test p > 0.05). 
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Table 3. Acceptability of multiparticulate formulation administered using an oral syringe 
(Sympfiny™) (n = 40 children); the dose volumes 0.5 mL, 1.2 mL and 2 mL, correlated to a mass of 
MPs of 0.32 g, 0.78 g and 1.29 g, respectively. 




the Doses ** 
Success in swallowing the 
formulation 
     
Completely swallowed 35 (87.5%) 22 (55.0%) 23 (57.5%) 25 (62.5%) 0.001 
Partially swallowed 3 (7.5%) 7 (17.5%) 4 (10.0%) 4 (10.0%) 0.433 
Chewed on 1 (2.5%) 1 (2.5%) 0 (0.0%) 1 (2.5%) 0.392 
Sample spat out 2 (5.0%) 3 (7.5%) 2 (5.0%) 0 (0.0%) 0.392 
Sample got stuck in throat 0 (0.0%) 1 (2.5%) 0 (0.0%) 0 (0.0%) 0.392 
Refused to take sample 1 (2.5%) 6 (15.0%) 11 (27.5%) 10 (25.0%) 0.001 
Sum of negative facial expressions (frequency) * 0.167 








Willingness to take the sample if a child were sick * <0.05 








* When children refused a sample, the data were not recorded; results were calculated based on 
evaluated samples (= total number of samples—refused samples). ** Friedman test, p value. 
3.2. Participants Hedonic Response 
Children evaluated grittiness, sample volume, mouthfeel, and taste of the doses using 5-point 
hedonic facial scales (Figure 3). Grittiness perception received high scores i.e., scores of 4 and 5 (where 
5 was very gritty) by 47% of children. On the contrary, other palatability parameters received positive 
to neutral ratings (i.e., scores 1, 2 and 3) in 70%, 67% and 63% of evaluations of volume, mouthfeel 
and taste, respectively. No association was found between the dose size and the rating of the sample 
taste or mouthfeel, including the grittiness (Wilcoxon’s test, p > 0.05). However, based on the sample 
volume, the children preferred the smallest dose of 0.5 mL (Wilcoxon’s test, p < 0.01, Figure 3). 
Participants’ voluntary feedback supported some of the findings on the hedonic scales. The taste 
of the MPs was described as “plain” or “tasteless”; however, the feeling in the mouth was found to 
be “very gritty”, “tickly” and “crunchy”. Moreover, for the larger doses (1.2 mL and 2.0 mL), the 
volume of the dose was often criticised by children—”it was a lot”, “too much”, and also by their 
parents “the dose is too big for his tongue”. This explained why the smallest dose received the most 
positive hedonic ratings. 
The effect that an alternative drink, to chase the MPs dose, had on palatability was evaluated. 
Based on hedonic scales, no difference between samples taken with water or a drink of choice was 
found (Wilcoxon’s test, p > 0.05, Figure 3). Children’s anecdotal comments were also contradictory 
on that matter, with some describing improvement of taste with a drink, while others stated that 
water was better to take with MPs. 
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Figure 3. Participant ratings of sample attributes: (A) grittiness, (B) mouthfeel and taste, (C) volume. 
Parts (A) and (B) show data pooled from all doses administered as there was no significant difference 
between doses (Wilcoxon test, after Bonferroni correction, p > 0.008); (C) shows data per dose, brackets 
represent statistically different doses (Wilcoxon test, after Bonferroni correction, p < 0.008). Centre 
lines represent the medians, box indicates the 25th and 75th percentiles, whiskers indicate spread of 
data, X represents mean. 
In general, children tended to give subjective feedback, as distinct from objective descriptions; 
their comments ranged from “amazing” through “disgusting” and “yuck”. Yet, the majority of the 
subjective comments were negative, in contrast to the findings of hedonic scales, which oscillated 
around neutral responses (the mode of all scores = 3). The reason behind this may be that children 
tend to prefer familiar or recognisable products [26] and MPs, as a novel product, are difficult to 
describe. The unfamiliarity of MPs was highlighted by children who were trying to relate them to a 
more familiar product like “flour” or “sugar”. 
Observation of negative facial expression was used as an indicator of sample disliking. The most 
commonly observed facial expression was “lips pressed”, observed in 37% of administrations, 
followed by “nose wrinkling” 31%, “brows pulled together and lowered” 23%, “eyes squeezed” 20%, 
“voice disgust” 11%, and “head shake” 6%. Children showed at least one negative facial expression 
in 56% of the administrations. Although the largest dose seemed to be causing most discomfort to 
children, the difference between samples was not statistically significant (Table 3). 
3.3. Willingness to Take the MPs Every Day as a Medicine 
The proportion of participants willing to take the sample every day if they were sick was used 
as a predictive measure of future and repeated acceptability, which is likely to influence adherence. 
The smallest dose was most acceptable among children. Based on their responses, 69.4% (27/39) of 
children would be willing to take the 0.5-mL dose of MPs every day if they were sick, in contrast to 
58.8% and 51.7% for 1.2-mL and 2.0-mL doses, respectively (Table 3). In relation to the findings based 
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on hedonic perception, the preference for the 0.5-mL dose can be contributed to by its small volume, 
rather than the taste or mouthfeel. 
A positive association was found between the willingness to take the dose every day as a 
medicine and ratings on the hedonic scales for all four parameters (Wilcoxon rank test, p > 0.05). For 
example, when the mouthfeel of the sample was acceptable (score ≥ 3), the child would tend to be 
willing to take the dose every day as a medicine. 
3.4. Water Consumed and Residual Multiparticulates in the Mouth 
Participants had free access to drinking water to aid sample swallowing, no suggestion on the 
amount of water to take was given. Children consumed 53 mL of water on average (median = 43 mL, 
min = 1 mL, max = 136 mL) (Figure 4A), in line with findings of Lopez et al. (2018b). The volume of 
water consumed was comparable between formulations (Wilcoxon test, p > 0.017). The volume of a 
drink of choice taken with the sample was not measured. 
After administration of the sample and consuming their preferred amount of water, children 
were asked whether they could still feel any MPs in their mouth (self-reported). Overall, children 
reported the feeling of residual MPs in the mouth on 52 occasions (39%). Reported perception of MPs 
in the mouth increased with larger sample volume, even though this trend was not statistically 
significant (Chi2, p > 0.05) (Figure 4B). 
Participants’ spontaneous descriptions of the samples reflected the necessity of a large amount 
of water to clean MPs residue from the mouth. Children described it as: “I had to take half the water 
out of the cup to wash it down” or “needed to drink”. Additionally, the researcher’s comments 
mentioned “lots of swishing of water to help swallow”. 
 
Figure 4. (A) Volume of water consumed as a function of a volume of multiparticulates (MPs) dose. 
Centre lines represent the medians, box indicates the 25th and 75th percentiles, whiskers indicate 
spread of data, X represents mean. (B) The proportion of children that reported they could still feel 
residual MPs in their mouth after sample intake, as a function of a volume of MPs dose. 
3.5. Impact of Age 
An association was found between children’s age and the proportion of each sample that was 
completely swallowed, as opposed to partially swallowed, spat out or refused (Kruskal–Wallis, p < 
0.05); no such association was found for willingness to take MPs if a child were sick (Kruskal–Wallis, 
p = 0.779) (Figure 5). When the ratings given for hedonic scores (grittiness, volume, taste and 
mouthfeel) were compared, there was no difference found between age groups (Kruskal-Wallis, p > 
0.05), suggesting the same level of liking of the sample in the whole study population. 
Children tended to choose responses at the middle and extreme ends of the scale as if they were 
responding on a three-point scale (binominal test, p < 0.001). Although such behaviour is typical for 
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younger children (5–6 years old) [27], here, it was observed across all age groups (Kruskal–Wallis, p 
= 0.989). 
3.6. Method of Administration 
Children who expressed a wish to self-administer doses of MPs were allowed to do so. Of nine 
children who self-administered the doses, there were three who were 10 years old, one who was 9 
years old, three who were 8 years old, one who was 6 years old and one who was 5 years old. They 
were more likely to completely swallow the sample, as compared with children who were given the 
dose by parent/carer (Chi2 test, p < 0.01); no such association was found for the willingness to take 
the dose every day as a medicine (Chi2 test, p = 0.514) (Figure 5). Moreover, these children tended to 
give more positive ratings on the volume hedonic scale than those who were given the dose by a 
parent/carer (Mann–Whitney test, p < 0.05), no such association was found for other hedonic 
measures. 
 
Figure 5. (A) Frequency of the dose being completely swallowed (n = 156) and (B) the number of 
observations when the child reported willingness to take a dose when sick (n = 129) by age group; (C) 
frequency of the dose being completely swallowed (n = 156) by the person administering the dose. 
The data were pooled from all doses administered. 
Based on the researcher’s comments and photographic documentation of the study, we observed 
several dosing techniques used by parents/children (Figure 6). Concerning the oral syringe 
positioning, some parents/children hover the oral syringe above the open mouth during dosing, 
while others do so above the child’s tongue sticking out of the mouth. Some children hold the oral 
syringe with lips or teeth. There were also instances of children blocking the oral syringe opening 
with their tongue, which effectively stopped the flow of MPs. A video of a parent administering a 
dose to a child is available in the Supplementary Materials. 
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Figure 6. Administration of a dose of MPs using an oral syringe Sympfiny™ by the parent (a) and by 
the participant themselves (b) (pictures obtained and reproduced with written parental consent). 
4. Discussion 
4.1. Effect of Dose Volume on Acceptability and Palatability 
The increasing volume of administered MPs negatively impacted the success of taking the 
sample and the child’s willingness to take a dose. These data suggest that the maximum dose of MPs 
that can be comfortably taken in a single mouthful by children may be limited; in our study 
acceptability reduced from 87.5% in terms of success in swallowing for the 0.5 mL (0.32 g) dose to 
55% for the 1.2 mL dose (0.78 g). This is of particular relevance for children who have a small oral 
cavity and lower saliva volume compared with adults (Watanabe et al., 2017). Similar findings of 
smaller dose volumes being preferred were previously reported in adults (Lopez et al., 2016). 
Based on participant hedonic ratings of the sample volume children showed a clear preference 
for the smallest dose, in line with other acceptability measures and anecdotal comments from 
participants. The sample grittiness was a dominant negative attribute which could be a cause of 
participants discomfort and sample dislike, as demonstrated by negative facial expressions and 
spontaneous feedback. Perception of a “gritty” feeling in the mouth produced by MPs was previously 
reported and related to the MPs size and amount (Kimura et al., 2015; Lopez et al., 2016). Besides, if 
the volume of powder or granulate is too large to be suspended in saliva, it can cause a dry and 
abrasive feeling (Mouritsen et al., 2017). The human mouth can perceive grittiness of particles as small 
as 6–10 µm (Imai et al., 1995), therefore, a certain level of grittiness of MPs is unavoidable. 
The study showed that the small volumes of MPs can be well accepted “as it is”, meaning 
without the need for a co-administration vehicle or adding sweeteners, flavourings. This is of 
importance, as in order to ease administration and improve the palatability of sprinkle dosage forms, 
mixing with food has been common practice (Food and Drug Administration, 2018b; World Health 
Organization, 2010). Several studies have shown, that administration of MPs in a viscous vehicle can 
mitigate the feeling of grittiness (Imai et al., 1995; Lopez et al., 2016; Lopez et al., 2018a). However, 
despite the potential to improve palatability, this additional step before administration increases the 
burden on the parent/carer and may actually decrease overall acceptability of the product 
(MacDonald et al., 2006). In addition, a necessity to mix MPs with a vehicle prior to administration 
would eliminate the benefit of dosing directly to the mouth offered by an oral syringe. 
4.2. Novelty of the Device 
The majority of children (87.5%) were familiar with oral syringes, yet administration of a 
different type of formulation (MPs) in an oral syringe was a new experience for both the children and 
their parents/caregivers. Usually, the novelty has a negative impact on one’s liking (Sondergaard and 
Edelenbo, 2008). It needs to be noted that the data presented are based on the experience and opinions 
of healthy participants after administration in a single study visit ranging in age from 4 to 12 years. 
(a) (b) 
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This single-day experience may not accurately represent long-term use, as the acceptability could 
change over time. On one hand familiarity and liking can increase with exposure to a novel product 
(Stolzenbach et al., 2013), on the other hand first negative impression can last over a long time. 
Nevertheless, previous research suggests that training, as well as positive attitudes towards taking a 
medication or a therapeutic regime, are good predictors of patient compliance (Ghuman et al., 2004; 
Kreivi et al., 2014). 
The results from this study were compared to a previous study where MPs dispersed in 3 mL 
water were administered from a medicine spoon. In the study of Lopez et al. (2018b), a dose of 0.5 g 
MPs was administered; the doses administered from the oral syringe were 0.32 g (0.5 mL), 0.78 g (1.2 
mL) and 1.29 g (2 mL); the particles used in both studies were of the same size and with the same 
coating enabling a direct comparison. The acceptability of MPs, in terms of willingness to take a 
sample every day if a child were sick, was much higher (64% of doses (from pooling data from two 
smaller doses 0.5 mL and 1.2 mL taken with water)) when dosed with an oral syringe compared to 
dosing on a spoon (17%). However, opposing results were found when the success of taking a dose 
was compared between a spoon and an oral syringe (89% vs. 71% completely swallowed doses, 
respectively). A higher success of taking a dose with a spoon could be attributed to a difference in 
administration mode. While a dose on a spoon was given in “one go”, administration with an oral 
syringe allowed to stop and resume dosing at any time during administration which resulted in some 
doses being only partially administered/swallowed. On the other hand, a higher willingness to take a dose 
with an oral syringe highlights the importance of the appropriate choice of administration device. 
4.3. Children Having an Active Role in Taking Medicine 
In a paediatric population, the attitude towards medicines and having an active role in taking 
them are important for adherence (Sanz, 2003). In this study, the nine children decided to self-
administer the dose of MPs (with the parental supervision). The results suggest that self-
administration increased the probability of the dose being completely swallowed and reduced the 
negative effect of a large volume. By self-administration, children could adjust the position and speed 
of dosing to their liking. It is known that the engagement of a child benefits the healthcare process 
and children who have basic knowledge about medicine related topics can better engage with the 
process of taking medications (Sanz, 2003). However, children usually have scarce knowledge and 
negative attitudes towards medicines (Hämeen-Anttila et al., 2006; Syofyan et al., 2019), which can 
pose a barrier to medicines administration. In this light, the population who took part in the study 
might not be fully representative of the general population. The participants had to verbally assent 
to take part in the study which implies at least neutral attitudes to medicines. 
4.4. Study Limitations and Future Work 
In this study, the participants were only provided with written instruction and no feedback 
during the use of oral syringe was given. Consequently, we could not establish whether training on 
the correct use of syringe affects the acceptability of a dose. For a novel device, precise instruction 
and training are crucial for the correct use. Lack of information on where to place the syringe in the 
mouth led to different methods of administration of MPs. Therefore, the determination of the most 
appropriate syringe location in the mouth for comfortable and successful dosing would be of interest. 
A possible further extension of this study would be to explore methods for administration of 
larger doses, for instance giving the dose in multiple pushes so that a child swallows smaller volume 
of MPs. This might be a feasible solution due to the presence of the valve system that allows stopping 
and starting the MPs flow. 
5. Conclusions 
The study demonstrates that the novel oral syringe being developed is an appropriate device for 
dispensing doses flexibly and administering neutral-tasting multiparticulate formulations directly to 
the mouth without the need for a co-administration vehicle. Based on acceptability in a paediatric 
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population, the smallest dose was easiest to completely swallow. The average participants’ hedonic 
ratings given for taste and mouthfeel were neutral, which highlights that the formulation with no 
additional sweeteners or flavourings can be highly acceptable in children when dosed directly to the 
mouth. Additionally, a drink of choice showed no improvement in swallowability when considering 
higher dose volumes. Self-administration was also noted to have a positive impact on the overall 
dosing experience when studying larger doses. 
Supplementary Materials: The following are available online at www.mdpi.com/1999-4923/12/9/806/s1, Figure 
S1: SympfinyTM ‘Instructions for use’ presented to the study participants. 
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